As a consequence of bronchodilation and LH decrease, at the 26th week the dyspnea degree, measured as TDI (Transitional Dyspnea Index) score was significantly (p < 0.001) improved in COPD patients treated with glycopyrronium compared to those given placebo, exceeding even the limit of clinically important difference and suggesting that patients perceived the improvement. The gene discussed is PLOD1; the disease is chronic obstructive pulmonary disease.